Clinical Pharmacology Training Grant
临床药理学培训补助金
基本信息
- 批准号:7674487
- 负责人:
- 金额:$ 8.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The Division of Clinical Pharmacology Postdoctoral Research Training Program at Georgetown University was established in July, 1988. It received support as an NIGMS sponsored training program in 1990. During the last 15 years the goals and objectives of the training program have remained unchanged, that is to provide a clinical and basic research experience in order to prepare the trainee to become an independent investigator.
During the time period growth in the Training Program has been exceptional, due in part to the strong institutional commitment to Clinical Pharmacology and in part to continuing recruitment to research oriented faculty who participate with enthusiasm as faculty for the Research Training Program. The applicant pool for Clinical Pharmacology training at Georgetown is now proven and national in scope. Presently the Program consists of 7 Core and 21 Participating Faculty and 6 postdoctoral fellows in training. Candidates for the program are physicians who have completed training in a clinical specialty. Highly qualified Ph.D. (or equivalent degree) applicants with clearly defined career goals in Clinical Pharmacology will also be considered for training. Training is for 2-3 years, with fellows strongly encouraged to complete 3 years unless they have substantial prior research experience. The research training is carried out under the supervision of a mentor from the training faculty, monitored on an ongoing basis by the Program Director. Research training is complemented by formal instruction in clinical pharmacology, clinical investigation, bioethics, pharmacometrics, other graduate courses as appropriate, training in the responsible conduct of research, as well as weekly research conferences, and clinical consulting rounds. A broad range of research opportunities are available to trainees including cardiovascular, molecular, immuno, neuropharmacology, population pharmacokinetics, and drug metabolism programs in the laboratories of the faculty. Graduates of the program accept positions in academics, the Food and Drug Administration, and industry.
描述(由申请人提供):乔治敦大学临床药理学博士后研究培训计划的划分,于1988年7月成立。它在1990年获得了诺格姆斯赞助培训计划的支持。在过去的15年中,培训计划的目标和目标一直保持不变,这是为了提供临床和基础研究经验,以便为受训者提供独立的调查员,以提供独立的调查员。
在培训计划的期间,在培训计划的增长非常出色,部分原因是机构对临床药理学的坚定承诺,部分原因是继续招募以研究为导向的教师,他们热情地参加了研究培训计划。乔治敦临床药理学培训的申请人池现已被证明和国家范围。目前,该计划包括7个核心和21名参与教职员工和6名博士后研究员。该计划的候选人是完成临床专业培训的医生。高素质博士(或同等学历)在临床药理学中具有明确定义的职业目标的申请人也将被视为培训。培训是2 - 3年,除非有实质性的研究经验,否则强烈鼓励研究员完成3年。研究培训是在培训学院的导师的监督下进行的,该培训由计划主管持续监控。研究培训得到了临床药理学,临床研究,生物伦理学,药物计量学,其他研究生课程的正式教学,对研究的负责任进行培训以及每周的研究会议和临床咨询回合。学员提供了广泛的研究机会,包括心血管,分子,免疫,神经药理学,人群药代动力学和药物代谢计划,并在该学院实验室中。该计划的毕业生接受学者,食品药品监督管理局和行业的职位。
项目成果
期刊论文数量(34)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.
细胞色素 P450 2C9 和 2B6 对 (S)-美芬妥英进行人 N-去甲基化。
- DOI:
- 发表时间:1998
- 期刊:
- 影响因子:0
- 作者:Ko,JW;Desta,Z;Flockhart,DA
- 通讯作者:Flockhart,DA
Ticlopidine inhibits phenytoin clearance.
噻氯匹定抑制苯妥英的清除。
- DOI:10.1053/cp.1999.v66.103277001
- 发表时间:1999
- 期刊:
- 影响因子:6.7
- 作者:Donahue,S;Flockhart,DA;Abernethy,DR
- 通讯作者:Abernethy,DR
Oocyte-specific differences in cell-cycle control create an innate susceptibility to meiotic errors.
- DOI:10.1016/j.cub.2011.03.003
- 发表时间:2011-04-26
- 期刊:
- 影响因子:9.2
- 作者:Nagaoka, So Iha;Hodges, Craig A.;Albertini, David F.;Hunt, Patricia Ann
- 通讯作者:Hunt, Patricia Ann
Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome.
抽动秽语综合征患者克拉霉素-匹莫齐特致命相互作用机制的研究。
- DOI:10.1097/00004714-200006000-00005
- 发表时间:2000
- 期刊:
- 影响因子:2.9
- 作者:Flockhart,DA;Drici,MD;Kerbusch,T;Soukhova,N;Richard,E;Pearle,PL;Mahal,SK;Babb,VJ
- 通讯作者:Babb,VJ
Nitric oxide inhibits Oct-1 DNA binding activity in cultured vascular smooth muscle cells.
一氧化氮抑制培养的血管平滑肌细胞中的 Oct-1 DNA 结合活性。
- DOI:10.1016/s0024-3205(97)01172-7
- 发表时间:1998
- 期刊:
- 影响因子:6.1
- 作者:Liu,XK;Abernethy,DR;Andrawis,NS
- 通讯作者:Andrawis,NS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Milton L. Brown其他文献
2‐Amino‐4‐(4‐chloro‐3‐methylphenyl)‐5‐propyl‐1,3‐thiazolium iodide
2-氨基-4-(4-氯-3-甲基苯基)-5-丙基-1,3-碘化噻唑鎓
- DOI:
10.1107/s1600536807009427 - 发表时间:
2007 - 期刊:
- 影响因子:0.9
- 作者:
M. Chruszcz;Yali Kong;Z. Dauter;Milton L. Brown;W. Minor - 通讯作者:
W. Minor
Comparative molecular field analysis of colchicine inhibition and tubulin polymerization for combretastatins binding to the colchicine binding site on beta-tubulin.
秋水仙碱抑制和考布他汀与 β-微管蛋白上秋水仙碱结合位点结合的微管蛋白聚合的比较分子场分析。
- DOI:
10.1016/s0968-0896(00)00068-7 - 发表时间:
2000 - 期刊:
- 影响因子:3.5
- 作者:
Milton L. Brown;J. Rieger;Timothy L. Macdonald - 通讯作者:
Timothy L. Macdonald
Bone Stromal Cells As Therapeutic Targets In Osseous Metastasis
骨基质细胞作为骨转移的治疗靶点
- DOI:
10.1007/1-4020-3414-8_21 - 发表时间:
2005 - 期刊:
- 影响因子:16.6
- 作者:
R. Sikes;C. Cooper;G. Beck;Freddie L. Pruitt;Milton L. Brown;G. Balian - 通讯作者:
G. Balian
Potential of Nurr1 interactions to disclose new Parkinson’s therapeutics
Nurr1 相互作用揭示帕金森病新疗法的潜力
- DOI:
- 发表时间:
2009 - 期刊:
- 影响因子:0
- 作者:
H. Federoff;Milton L. Brown;S. Dakshanamurthy;K. Maguire - 通讯作者:
K. Maguire
Block of human NaV1.5 sodium channels by novel α-hydroxyphenylamide analogues of phenytoin
新型苯妥英 α-羟基苯酰胺类似物阻断人 NaV1.5 钠通道
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:0
- 作者:
P. W. Lenkowski;Seong;James D. Anderson;Milton L. Brown;M. Patel - 通讯作者:
M. Patel
Milton L. Brown的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Milton L. Brown', 18)}}的其他基金
Novel anti-metastasis agents for triple negative breast cancer
用于三阴性乳腺癌的新型抗转移剂
- 批准号:
8591859 - 财政年份:2013
- 资助金额:
$ 8.34万 - 项目类别:
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR Desensitizers
选择性α4β2神经元nAChR脱敏剂的合成与优化
- 批准号:
8124490 - 财政年份:2010
- 资助金额:
$ 8.34万 - 项目类别:
Sodium Channel Blockers as Inhibitors of Prostate Cancer
钠通道阻滞剂作为前列腺癌的抑制剂
- 批准号:
7362243 - 财政年份:2004
- 资助金额:
$ 8.34万 - 项目类别:
Sodium Channel Blockers as Inhibitors of Prostate Cancer
钠通道阻滞剂作为前列腺癌的抑制剂
- 批准号:
7071136 - 财政年份:2004
- 资助金额:
$ 8.34万 - 项目类别:
Sodium Channel Blockers as Inhibitors of Prostate Cancer
钠通道阻滞剂作为前列腺癌的抑制剂
- 批准号:
7256928 - 财政年份:2004
- 资助金额:
$ 8.34万 - 项目类别:
Sodium Channel Blockers as Inhibitors of Prostate Cancer
钠通道阻滞剂作为前列腺癌的抑制剂
- 批准号:
7446668 - 财政年份:2004
- 资助金额:
$ 8.34万 - 项目类别:
Sodium Channel Blockers as Inhibitors of Prostate Cancer
钠通道阻滞剂作为前列腺癌的抑制剂
- 批准号:
6731350 - 财政年份:2004
- 资助金额:
$ 8.34万 - 项目类别:
Sodium Channel Blockers as Inhibitors of Prostate Cancer
钠通道阻滞剂作为前列腺癌的抑制剂
- 批准号:
6889277 - 财政年份:2004
- 资助金额:
$ 8.34万 - 项目类别:
相似国自然基金
权力何以授予:目标理论视角下领导授权行为的形成机制研究
- 批准号:71702005
- 批准年份:2017
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy
虚拟药物筛选揭示了心肌细胞肥大的情境依赖性抑制
- 批准号:
10678351 - 财政年份:2023
- 资助金额:
$ 8.34万 - 项目类别:
Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase
使用 Cav3 通道和可溶性环氧化物水解酶的 IND 双重抑制剂开发可卡因使用障碍的新型治疗方法
- 批准号:
10786151 - 财政年份:2023
- 资助金额:
$ 8.34万 - 项目类别: